CatalYm GmbH clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   Visugromab in Combination With Immunochemotherapy in 1L Treatment…Visugromab in Combination With Immunochemotherapy in 1L Treatment · Metastatic NSCLC

   Trial sites expanded: 42 → 51 locations

   CatalYm GmbH·Phase 2· NCT07098988· Registry history of NCT07098988 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Minor

   VINCIT · Visugromab in Cachexia International Trial

   Trial sites expanded: 71 → 74 locations

   CatalYm GmbH·Phase 2/3· NCT07112196· Registry history of NCT07112196 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

3. Minor

   GDFATHERHCC01 · Visugromab, Nivolumab and Lenvatinib Compared…GDFATHERHCC01 · Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

   Trial sites expanded: 14 → 23 locations

   CatalYm GmbH·Phase 2· NCT07219459· Registry history of NCT07219459 on ClinicalTrials.gov (opens the registry)

   Sep 23, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.